JUBLINGREA Jubilant Ingrevia Q3 FY26 results (Oct–Dec 2025) and concall
Jubilant Ingrevia reported stable overall business performance in Q3 FY26 despite softer pricing across all segments, driven by strong volume growth. The company achieved an 8% increase in 9-month EBITDA and maintained Specialty Chemicals margins above 25%. Key milestones include the upcoming commercialization of a major CDMO order and progress in capacity expansion, while navigating pricing pressures in Nutrition and Chemical Intermediates.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 0.6%, net profit down 31.9% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 1,057 | 1,051 | 1,038 | 1,121 | 1,051 −1% |
| EBITDA | 138 | 147 | 142 | 135 | 126 −9% |
| Net profit | 69 | 74 | 75 | 69 | 47 −32% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
